Metastatic Cancer clinical trials

Explore recruiting metastatic cancer clinical trials.

Recruiting metastatic cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

AcSé pemigatinib: Phase II trial evaluating the efficacy of pemigatinib in patients with recurrent and/or metastatic solid tumor harboring a FGFR alteration

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy

Czechia, Poland, Germany, Netherlands, Spain, Ireland +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination with other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd–Sponsored Trastuzumab Emtansine Study

Poland, Spain, Portugal, France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Monalizumab and MEDI5752 in patients with MSI and/or dMMR metastatic cancer (MONAMI)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

PARASTOP – Paracetamol with Strong Opioids. A randomized, double-blind, parallel-group non-inferiority phase III withdrawal trial of paracetamol versus placebo in conjunction with opioids for moderate to severe cancer-related pain

Norway

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Metastatic Cancer trials by city

Metastatic Cancer in Toronto Metastatic Cancer in Vancouver Metastatic Cancer in Montreal Metastatic Cancer in Calgary Metastatic Cancer in Edmonton Metastatic Cancer in Ottawa Metastatic Cancer in Winnipeg Metastatic Cancer in Quebec City Metastatic Cancer in Hamilton Metastatic Cancer in Kitchener Metastatic Cancer in London Metastatic Cancer in Halifax Metastatic Cancer in New York Metastatic Cancer in Los Angeles Metastatic Cancer in Chicago Metastatic Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease